This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Go back to News
Disc Medicine claims PhII win for repurposed ex-Roche drug in rare blood disorder
When Disc Medicine closed a $62.5 million raise led by Bain Capital earlier this year, the biotech’s CEO John Quisel pointed to the stream of clinical readouts in blood disorders it is expecting as the impetus.
